Advertisement
AMGN or GILD or NVS
Which Stock Would AI Choose? Amgen (AMGN) vs. Gilead Sciences (GILD) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- AMGN reported strong Q1 2026 results with 6% revenue growth and earnings beat, boosting recent sentiment.
- GILD maintains defensive positioning from stable HIV franchise revenues amid upcoming Q1 earnings and oncology expansions.
- NVS showed mixed Q1 results with slight revenue dip but positive clinical progress in key therapies.
- AMGN trades at a trailing P/E around 23, higher than GILD's 19 but reflecting growth momentum.
- All three exhibit relative stability in the healthcare sector, with NVS leading one-year returns near 30%.
- Recent manufacturing investments by AMGN signal long-term capacity expansion.
Introduction
This comparison evaluates AMGN, GILD, and NVS, three leading healthcare stocks in the biotechnology and pharmaceutical sectors. Investors seeking exposure to innovative therapies, stable dividends, and defensive growth amid market volatility may find value in analyzing their relative performance. With recent earnings cycles highlighting revenue trends and pipeline advancements, this review aids traders assessing momentum, valuation, and sector positioning in the current environment.
AMGN Overview and Recent Performance
Amgen Inc. (AMGN) is a biotechnology pioneer focused on oncology, inflammation, and rare diseases, with blockbuster drugs driving revenue. In recent quarters, the stock has shown resilience, trading around $325 amid broader market pressures. Q1 2026 revenues rose 6% year-over-year to $8.6 billion, with adjusted EPS of $5.15 exceeding estimates, fueled by volume growth in key products. Sentiment has been supported by a $300 million U.S. manufacturing investment and a dividend hike to $2.52 per share, underscoring operational confidence. Year-to-date returns hover near 0.8%, with one-year gains at 18%, reflecting steady performance despite recent pullbacks.
GILD Overview and Recent Performance
Gilead Sciences Inc. (GILD) specializes in antivirals, particularly HIV treatments, alongside oncology and inflammation portfolios. The stock, near $131, has maintained stability as a defensive play. Recent market activity features anticipation for Q1 earnings on May 7, with estimates at $1.89 EPS and $6.89 billion revenue. Prior Q4 2025 revenues grew 4.7% to $7.93 billion, bolstered by HIV steadiness despite competitive pressures. Acquisitions like Arcellx enhance oncology prospects, while forward P/E around 15 suggests value. Performance has outpaced the S&P 500 in select sessions, driven by reliable franchise revenues.
NVS Overview and Recent Performance
Novartis AG (NVS), a global pharmaceutical leader, emphasizes innovative medicines in immunology, neuroscience, and cardiovascular areas. Shares around $147 have faced recent softness, down 4% over the past month. Q1 2026 operational sales grew modestly, though reported revenue dipped 0.9% to $13.11 billion amid currency effects. Positive Phase III data for Fabhalta supports pipeline momentum. YTD returns stand at 6.3%, with one-year gains near 30%, highlighting stronger long-term positioning despite quarterly variability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the top 25 performers from over 351 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and styles like trend-following, momentum, and fundamental analysis. These curated bots adapt to current market conditions, delivering impressive stats: annualized returns ranging from 23% to 162%, win rates of 51% to 88%, profit factors up to 11.7, and profit-to-drawdown ratios exceeding 17. Virtual and brokerage agents employ AI/ML for real-time signals, often with take-profit/stop-loss corridors (e.g., TP 3%/SL 2%). Explore these high-performing options to enhance your trading edge.
Head-to-Head Comparison
AMGN, GILD, and NVS operate in healthcare but differ in focus: AMGN's biotech emphasis on high-margin biologics contrasts GILD's HIV dominance (stable cash cow) and NVS's diversified global portfolio. Growth drivers include AMGN's volume expansion versus GILD's oncology bets and NVS's clinical wins. Recent momentum favors AMGN post-earnings, while NVS leads longer-term returns. Risks involve patent cliffs and R&D costs across all; GILD offers lowest forward P/E sensitivity. Sentiment tilts toward dividend reliability in volatile markets.
Tickeron AI Verdict
Tickeron's AI currently leans toward AMGN based on earnings consistency, manufacturing catalysts, and relative stability versus peers. Strong Q1 beats and capacity investments position it favorably amid healthcare trends, though GILD and NVS offer compelling value and diversification probabilities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileGILD’s FA Score has 3 green FA rating(s), and NVS’s FA Score reflects 4 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- GILD’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while GILD’s TA Score has 5 bullish TA indicator(s), and NVS’s TA Score reflects 6 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 4 bearish.
- GILD’s TA Score: 5 bullish, 3 bearish.
- NVS’s TA Score: 6 bullish, 3 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.03% price change this week, while GILD (@Pharmaceuticals: Major) price change was +1.09% , and NVS (@Pharmaceuticals: Major) price fluctuated +1.83% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.03%. For the same industry, the average monthly price growth was -0.75%, and the average quarterly price growth was +2.71%.
Reported Earning Dates
AMGN is expected to report earnings on Jul 30, 2026.
GILD is expected to report earnings on Jul 30, 2026.
NVS is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.03% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | GILD | NVS | |
| Capitalization | 182B | 168B | 284B |
| EBITDA | 16.7B | 14.5B | 22.4B |
| Gain YTD | 3.455 | 10.564 | 10.711 |
| P/E Ratio | 23.40 | 18.36 | 21.23 |
| Revenue | 37.2B | 29.7B | 56.6B |
| Total Cash | 12B | 7.64B | 6.98B |
| Total Debt | 57.3B | 22.2B | 47B |
AMGN | GILD | NVS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 9 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 22 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 32 | 12 | 9 | |
SMR RATING 1..100 | 13 | 22 | 27 | |
PRICE GROWTH RATING 1..100 | 58 | 52 | 51 | |
P/E GROWTH RATING 1..100 | 58 | 68 | 29 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (13) in the Pharmaceuticals Major industry is in the same range as AMGN (18) in the Biotechnology industry, and is in the same range as GILD (22) in the Biotechnology industry. This means that NVS's stock grew similarly to AMGN’s and similarly to GILD’s over the last 12 months.
NVS's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is in the same range as GILD (12) in the Biotechnology industry, and is in the same range as AMGN (32) in the Biotechnology industry. This means that NVS's stock grew similarly to GILD’s and similarly to AMGN’s over the last 12 months.
AMGN's SMR Rating (13) in the Biotechnology industry is in the same range as GILD (22) in the Biotechnology industry, and is in the same range as NVS (27) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to GILD’s and similarly to NVS’s over the last 12 months.
NVS's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as GILD (52) in the Biotechnology industry, and is in the same range as AMGN (58) in the Biotechnology industry. This means that NVS's stock grew similarly to GILD’s and similarly to AMGN’s over the last 12 months.
NVS's P/E Growth Rating (29) in the Pharmaceuticals Major industry is in the same range as AMGN (58) in the Biotechnology industry, and is somewhat better than the same rating for GILD (68) in the Biotechnology industry. This means that NVS's stock grew similarly to AMGN’s and somewhat faster than GILD’s over the last 12 months.
| AMGN | GILD | NVS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 57% | 1 day ago 48% | 2 days ago 29% |
| Stochastic ODDS (%) | 1 day ago 50% | 1 day ago 33% | 2 days ago 41% |
| Momentum ODDS (%) | 1 day ago 51% | 1 day ago 58% | 2 days ago 49% |
| MACD ODDS (%) | 1 day ago 46% | 1 day ago 72% | 2 days ago 57% |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 60% | 2 days ago 53% |
| TrendMonth ODDS (%) | 1 day ago 49% | 1 day ago 48% | 2 days ago 38% |
| Advances ODDS (%) | 7 days ago 56% | 1 day ago 61% | 7 days ago 52% |
| Declines ODDS (%) | 9 days ago 51% | 5 days ago 46% | 9 days ago 45% |
| BollingerBands ODDS (%) | 1 day ago 59% | 1 day ago 47% | 2 days ago 41% |
| Aroon ODDS (%) | 1 day ago 52% | 1 day ago 52% | 2 days ago 33% |
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.